Nanotechnology: A new approach for ocular drug delivery system

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 2, 2012, Pages 105-112

  Mudgil, Meetali ^a   Gupta, Nidhi ^a   Nagpal, Manju ^a   Pawar, Pravin ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

Nanocarriers; Ocular drug delivery

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CARVEDILOL; CLORICROMEN; CYCLOSPORIN A; DICLOFENAC; EUDRAGIT; LEVOFLOXACIN; MITOTANE; NANOCARRIER; NANOGEL; NANOMATERIAL; NANOPARTICLE; NANOSUSPENSION; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; POLOXAMER; POLYGLACTIN; POLYMER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLID LIPID NANOPARTICLE; SPARFLOXACIN; STEROID; SULFACETAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; EYE; EYE DISEASE; GEL; GELATION; HUMAN; HYDROPHOBICITY; IONIC STRENGTH; MOLECULAR WEIGHT; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PH; REVIEW; SUSPENSION; UVEITIS;

EID: 84859953635     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Kumar M, Kulkarni GT. Recent advances in ophthalmic drug delivery system. Int J Pharm Pharm Sci 2012; 4(1):387-394.
2. Derwent JJK, Mieler WF. Thermo-responsive hydrogels as a new ocular drug delivery platform to the posterior segment of eye. Trans Am Ophthalmol Soc 2008; 106:206-214.
3. Joshi A. Microparticulates for ophthalmic drug delivery. J Ocul Pharmacol 1994; 10(1):29-45.
4. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009; 136(1):2-13.
5. Nagarsenker MS, Londhe VY and Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm 1999; 190(1):63-71.
6. Yoel G, Guy K. Use of collagen shields for ocular surface drug delivery. Expert Rev Ophthalmol 2008; 3(6):627-633.
7. Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL. Soluble gentamicin ophthalmic inserts as a drug delivery system. Arch Ophthalmol 1978; 96(5):885-887.
8. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005; 102(1):23-38.
9. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF. Effect of iontophoresis on transcorneal permeation 'in vitro' of two β-blocking agents, and on corneal hydration. Int J Pharm 2003; 250(2):423-9.
10. Antoine BR, Francine BC, David B, Robert G, Florence D. Polymeric nanoparticles for drug delivery to the posterior segment of the eye. CHIMIA International Journal for Chemistry 2005; 59(6):344-347.
11. Selvaraj S, Karthikeyan J, Saravankumar N. Chitosan loaded microspheres as an ocular delivery system for acyclovir. Int J Pharm Pharm Sci 2012; 4(1):125-132.
12. Jitendra, Sharma PK, Banik A, Dixit S. A new trend: ocular drug delivery system. Pharma science monitor 2011; 2(3):1-25.
13. Koteshwara KB, Reddy MS, Naha A, Nampoothiri M. Nanosuspensions: a novel drug delivery approach. IJRAP 2011; 2(1):162-165.
14. Patel M, Shah A, Patel NM, Patel MR, Patel KR. Nanosuspension: a novel approach for drug delivery system. JPSBR 2011; 1(1):1-10.
15. Kamble VA, Jagdale DM, Kadam VJ. Nanosuspension a novel drug delivery system. IJPBS 2010; 1(4):352-360.
16. Wagh KS, Patil SK, Akarte AK, Baviskar DT. Nanosuspension-a new approach of bioavailability enhancement. IJPSRR 2011; 8(2):61-65.
17. Patel VR, Agrawal YK. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res 2011; 2(2):81-87.
18. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water- soluble drugs. Drug Discov Today 2011; 16:354-360.
19. Keck C, Kobierski S, Mauludin R, Muller RH. Second generation of drug nanocrystals for delivery of poorly soluble drugs: smart crystals technology. DOSIS 2008; 24(2):124-128.
20. Nesalin JAJ, Smith AA. Nanoparticles as an invisible drug delivery system. Journal of Pharmacy Research 2011; 4(2):373-377
21. Kabanov AV. Polymer genomics: An insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 2006; 58(15):1597-621.
22. Lakshmi P, Kumar GA. Nanosuspension technology: a review. Int J Pharm Pharm Sci 2010; 2(4):35-40.
23. Venkatesh T, Reddy AK, Maheswari JU, Dalith MD, Kumar CKA. Nanosuspensions: ideal approach for the drug delivery of poorly water soluble drugs. Der Pharmacia Lettre 2011; 3(2):203-213.
24. Abhilash M. Potential applications of nanoparticles. IJPBS 2010; 1(1):1-12.
25. Chingunpituk J. Nanosuspension technology for drug delivery. Walailak J Sci & Tech 2007; 4(2):139-153.
26. Sivasankar M, Kumar BP. Role of nanoparticles in drug delivery system. IJRPBS 2010; 1(2):41-66.
27. Kayser O, Lemke A, Hernandez-Trejo N. The Impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005; 6(1):3-5.
28. Bhargavi R. A technical review of nanosuspensions. IJPT 2011; 3(3):1503-1511.
29. Prabhakar C, Krishna KB. A review on nanosuspensions in drug delivery. IJPBS 2011; 2(1):549-558.
30. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. COSSMS 2002; 6:319-327.
31. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003; 20(4):584-90.
32. Das SK, Tucker IG, Hill DJ, Ganguly N. Evaluation of poly (isobutylcyanoacrylate) nanoparticles for mucoadhesive ocular drug delivery. I. Effect of formulation variables on physicochemical characteristics of nanoparticles. Pharm Res 1995; 12:534-40.
33. Vega E, Egea MA, Valls O, Espina M, Garcia ML. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci 2006; 95:2393-405.
34. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 1993; 10(1):80-7.
35. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol 2003; 55(11):1451-63.
36. Vandervoort J, Ludwig A. Preparation and evaluation of drugloaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm 2004; 57(2):251-61.
37. Irache JM, Merodio M, Arnedo A, Camapanero MA, Mirshahi M, Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 2005; 5:293-305.
38. Marcato PD, Duran N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 2008; 8:1-14.
39. Mohanraj VJ, Chen Y. Nanoparticles - A review. Trop J Pharm Res 2006; 5(1):561-573.
40. Mandal B, Alexander KS, Riga AT. Sulfacetamide loaded Eudragit RL100 nanosuspension with potential for ocular delivery. J Pharm Pharmaceut Sci 2010; 13(4): 510-523.
41. Kalimuthu S, Yadav AV. Formulation and evaluation of carvedilol loaded Eudragit e 100 nanoparticles. Int J PharmTech Res 2009; 1(2):179-183.
42. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010; 6:324-333.
43. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, and Mittal A. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target 2011; 19(6):409-17.
44. Dandagi P, Kerur S, Mastiholimath V, Kulkarni A. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. IJPR 2009; 8 (2):79-86.
45. Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene, AAPS PharmSciTech 2006; 7(1):27.
46. Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Unlu N. Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Release 2011; 151(3):286-94.
47. Adibkia K, Reza M, Shadbad S, Nokhodchi A, Javadzedeh A, Jalali MB, Barar J, Mohammadi G, and Omidi Y. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 2007; 15(6):407-16.
48. Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine 2011; 7(2):242-7.
49. Ahuja M, Dhake SA, Sharma SK and Majumdar KD. Diclofenacloaded Eudragit S100 nanosuspension for ophthalmic delivery. J Microencapsul 2011; 28(1): 37-45.
50. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 2009; 5(1):90-5.
51. Ali HSM, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom- up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009; 375(1-2):107-13.
52. Yoncheva K, Vandervoort J, Ludwig A. Development of mucoadhesive poly (lactide-coglycolide) nanoparticles for ocular application. Pharm Dev Technol 2011; 6(1):29-35.
53. Lin H, Yu S, Kuo C, Kao H, Lo Y and Lin Y. Pilocarpine-loaded chitosan-PAA nanosuspension for ophthalmic delivery, J Biomater Sci Polym Ed 2007; 18(2):205-21.
54. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002; 16(1-2):53-61.
55. Pignatello R, Bucolo C, Spedalieri G, Maltese A and Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002; 23(15): 3247-55.
56. Akhter S, Talegaonkar S, Khan ZI, Jain GK, Khar RK, Ahmad FJ. Assessment of ocular pharmacokinetics and safety of Ganciclovir loaded nanoformulations. J Biomed Nanotechnol 2011; 7(1):144-5.
57. Mohammadi G, Nokhodchi A, Barzegar JM, Lotfipour F, Adibkia K, Ehyaei N, Valizadeh H. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 2011; 88(1):39-44.
58. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartratrateeudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech 2011; 12(4):1087-101.
59. Javadzadeh Y, Ahadi F, Davaran S, Mohammadi G, Sabzevari A, Adibkia K. Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. Colloids Surf B Biointerfaces 2010; 81(2):498-502.
60. Jimenez N, Galan J, Vallet A, Egea MA, Garcia ML. Methyl trypsin loaded poly (D,L-lactide-coglycolide) nanoparticles for contact lens care. J Pharm Sci 2010; 99(3):1414-26.
61. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. JPP 2004; 56:827-840.
62. Kassem MA, Rahman AAA, Ghorab MB, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007; 340(1-2):126-33.
63. Pardeike J, Muller RH. Dermal and ocular safety of the new phospholipase A2 inhibitors PX-18 and PX-13 formulated as drug nanosuspension. J Biomed Nanotechnol 2009; 5(4):437-44.
64. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric Nanoparticles. Nanomedicine 2006; 2:8-21.
65. Yadav M, Ahuja M. Preparation and evaluation of nanoparticles of gum cordia, an anionic polysaccharide for ophthalmic delivery. Carbohydrate polymers 2010; 81(4):871-877.
66. Wu X, Xin M, Yang G L, Shi W. The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits. J Pharm Sci 2011; 100:1350-1361.
67. Singh KH, Shinde UA. Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. Pharmazie 2011; 66(8):594-9.
68. Konat ZG, Contreras-Ruiz L, Parraga JE, Loopez-Garciia A, Romero Bello R, Diebold Y, Seijo B, Saanchez A. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. Mol Pharm 2011; 8(5): 1783-8.
69. Mahmoud AA, El-Feky GS, Kamel R, Awad GE. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011; 413(1-2):229-36.
70. Zorzi GK, Parraga JE, Seijo B, Sanchez A. Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy. Macromol Biosci 2011; 11(7):905-13.
71. Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study. Chem Pharm Bull (Tokyo) 2011; 59(2):272-8.
72. Jain GK, Pathan SA, Akhter S, Jayabalan N, Talegaonkar S, Khar RK, Ahmad FJ. Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery system. Colloids Surf B Biointerfaces 2011; 82(2):397-403.
73. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target 2010; 18(4):292-302.
74. Badawi AA, El- Laithy HM, El Qidra RK, El mofty H, El dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 2008; 31(8):1040-1049.
75. Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001; 224(1-2):159-68
76. Banavath H, Sivarama RK, Ansari T, Ali S, Pattnaik G. Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs. IJPSR 2010; 1(9):1-11.
77. Kim JH, Jang SW, Han SD, Hwang HD, Choi HG. Development of a novel ophthalmic cyclosporine A-loaded nanosuspension using top-down media milling methods. Pharmazie 2011; 66(7): 491-5.
78. Thote AJ, Gupta RB. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustain release. Nanomedicine 2005; 1(1):85-90.
79. Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO(2) antisolvent with enhanced mass transfer. Int J Pharm 2001; 228(1-2):19-31.